IL251790B - Compounds include thiazole for the treatment of culture diseases - Google Patents
Compounds include thiazole for the treatment of culture diseasesInfo
- Publication number
- IL251790B IL251790B IL251790A IL25179017A IL251790B IL 251790 B IL251790 B IL 251790B IL 251790 A IL251790 A IL 251790A IL 25179017 A IL25179017 A IL 25179017A IL 251790 B IL251790 B IL 251790B
- Authority
- IL
- Israel
- Prior art keywords
- thiazolyl
- containing compounds
- proliferative diseases
- treating proliferative
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 125000000335 thiazolyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067178P | 2014-10-22 | 2014-10-22 | |
| PCT/US2015/056899 WO2016065138A1 (en) | 2014-10-22 | 2015-10-22 | Thiazolyl-containing compounds for treating proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251790A0 IL251790A0 (en) | 2017-06-29 |
| IL251790B true IL251790B (en) | 2019-08-29 |
Family
ID=55761545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251790A IL251790B (en) | 2014-10-22 | 2017-04-19 | Compounds include thiazole for the treatment of culture diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10112957B2 (https=) |
| EP (2) | EP3715346B1 (https=) |
| JP (1) | JP6788583B2 (https=) |
| AU (1) | AU2015335788B2 (https=) |
| CA (1) | CA2965178C (https=) |
| IL (1) | IL251790B (https=) |
| WO (1) | WO2016065138A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856223B2 (en) | 2013-12-13 | 2018-01-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| RS61991B1 (sr) * | 2016-07-14 | 2021-07-30 | Lilly Co Eli | Derivati pirazolilaminobenzimidazola kao jak inhibitori |
| CN110099684B (zh) * | 2016-11-03 | 2022-11-11 | 科尔沃斯制药股份有限公司 | 用于调节白介素-2诱导性t细胞激酶的化合物和方法 |
| KR102328682B1 (ko) * | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| CN109265455B (zh) * | 2018-11-09 | 2020-08-18 | 新发药业有限公司 | 一种达沙替尼的制备方法 |
| MX2022010391A (es) * | 2020-02-26 | 2022-09-05 | Daewoong Pharmaceutical Co Ltd | Metodo de preparacion de derivados de amina heterociclica. |
| EP4087574A4 (en) * | 2020-03-06 | 2024-01-17 | National Health Research Institutes | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES |
| WO2024111626A1 (ja) * | 2022-11-25 | 2024-05-30 | カルナバイオサイエンス株式会社 | 新規チアゾール誘導体 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| EP1071658B1 (en) | 1998-04-17 | 2004-06-16 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
| CA2338121A1 (en) | 1998-08-04 | 2000-02-17 | Astrazeneca Ab | Amide derivatives useful as inhibitors of the production of cytokines |
| EP1115707B1 (en) | 1998-09-25 | 2003-11-12 | AstraZeneca AB | Benzamide derivatives and ther use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| SI1569907T1 (sl) | 2002-12-13 | 2016-06-30 | Ym Biosciences Australia Pty Ltd | Na nikotinamidu osnovani kinazni inhibitorji |
| UY29300A1 (es) | 2004-12-22 | 2006-07-31 | Astrazeneca Ab | Compuestos quimicos |
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| RU2368602C2 (ru) * | 2005-01-26 | 2009-09-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| US7375951B2 (en) * | 2006-07-07 | 2008-05-20 | Lutron Electronics Co., Inc. | Load control device having a split enclosure |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| US8101610B2 (en) | 2005-11-14 | 2012-01-24 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
| US20070155746A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| AU2008282728B2 (en) | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
| EP2508523B2 (en) | 2007-10-23 | 2019-04-17 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| EP2222166B9 (en) | 2007-12-10 | 2012-11-07 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| AU2009289378A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| IN2012DN02493A (https=) | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| US20140080810A1 (en) | 2010-11-15 | 2014-03-20 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
| WO2012161877A1 (en) | 2011-05-23 | 2012-11-29 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| KR20180084153A (ko) | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| MX2014003994A (es) | 2011-10-03 | 2014-05-07 | Syngenta Participations Ag | Derivados insecticidas de 2-metoxobenzamida. |
| JP2014528451A (ja) | 2011-10-04 | 2014-10-27 | ギリアード カリストガ エルエルシー | Ｐｉ３ｋの新規キノキサリン阻害剤 |
| MX2014005289A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de piperazina alquilados. |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| CN103405429A (zh) | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US9856223B2 (en) | 2013-12-13 | 2018-01-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
-
2015
- 2015-10-22 US US15/518,541 patent/US10112957B2/en active Active
- 2015-10-22 EP EP20161511.9A patent/EP3715346B1/en active Active
- 2015-10-22 WO PCT/US2015/056899 patent/WO2016065138A1/en not_active Ceased
- 2015-10-22 JP JP2017522375A patent/JP6788583B2/ja active Active
- 2015-10-22 CA CA2965178A patent/CA2965178C/en active Active
- 2015-10-22 AU AU2015335788A patent/AU2015335788B2/en active Active
- 2015-10-22 EP EP15852450.4A patent/EP3209648B1/en active Active
-
2017
- 2017-04-19 IL IL251790A patent/IL251790B/en active IP Right Grant
-
2018
- 2018-10-24 US US16/169,972 patent/US10464949B2/en not_active Expired - Fee Related
-
2019
- 2019-11-01 US US16/672,198 patent/US10844077B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2965178A1 (en) | 2016-04-28 |
| IL251790A0 (en) | 2017-06-29 |
| US10844077B2 (en) | 2020-11-24 |
| US20190119301A1 (en) | 2019-04-25 |
| AU2015335788A1 (en) | 2017-05-04 |
| EP3209648A4 (en) | 2018-07-25 |
| US10112957B2 (en) | 2018-10-30 |
| EP3209648A1 (en) | 2017-08-30 |
| US20170233411A1 (en) | 2017-08-17 |
| US10464949B2 (en) | 2019-11-05 |
| US20200165267A1 (en) | 2020-05-28 |
| EP3715346B1 (en) | 2024-01-03 |
| EP3209648B1 (en) | 2020-03-11 |
| AU2015335788B2 (en) | 2020-07-30 |
| JP6788583B2 (ja) | 2020-11-25 |
| CA2965178C (en) | 2023-09-26 |
| JP2017537886A (ja) | 2017-12-21 |
| EP3715346A1 (en) | 2020-09-30 |
| WO2016065138A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500001I1 (hu) | Antitestkészítmények daganatkezelésre | |
| IL304252A (en) | Cancer treatment methods | |
| IL289947A (en) | A method for treating cancer | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| IL285077A (en) | Compounds for the treatment of cancer | |
| IL252716A0 (en) | Anti-csf1r antibodies for the treatment of pvns | |
| IL249229A0 (en) | Compounds for the treatment of brain cancer | |
| IL251790A0 (en) | Compounds include thiazole for the treatment of culture diseases | |
| GB201415569D0 (en) | Therapeutic Compounds | |
| HUE049600T2 (hu) | GLS1 inhibitorok betegségek kezelésére | |
| SG11201605070UA (en) | Novel methods for treating cancer | |
| GB201416273D0 (en) | Therapeutic compounds | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
| AU2014904697A0 (en) | Compounds for treating cancer | |
| GB201418676D0 (en) | Compounds for use | |
| GB201409792D0 (en) | Compounds for use | |
| GB201409405D0 (en) | Therapeutic compounds | |
| GB201407122D0 (en) | Therapeutic compounds | |
| GB201406748D0 (en) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |